Currency In USD
| Previous Close | 4.18 |
| Open | 4.19 |
| Day High | 4.19 |
| Day Low | 4.11 |
| 52-Week High | 5.36 |
| 52-Week Low | 3.53 |
| Volume | 0 |
| Average Volume | 4,083 |
| Market Cap | 154.17M |
| PE | -2.41 |
| EPS | -1.71 |
| Moving Average 50 Days | 4.15 |
| Moving Average 200 Days | 4.24 |
| Change | -0.07 |
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
GlobeNewswire Inc.
Feb 26, 2026 6:00 AM GMT
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
GlobeNewswire Inc.
Feb 26, 2026 6:00 AM GMT
Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac)ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb.
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
GlobeNewswire Inc.
Feb 02, 2026 6:00 AM GMT
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotope